Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is KAI-4729?
Plain language first. The technical label stays, but it never stands alone.Overview
It hits the same three targets as retatrutide but is a different peptide, designed with higher GLP-1 receptor affinity. A 12-week phase 1 in China produced up to 16% weight loss in ten people. Phase 2 trials in obesity, fatty liver disease, type 2 diabetes and kidney disease are approved or starting in China.
KAI-4729, called HRS-4729 by its Chinese developer Jiangsu Hengrui, is a triple agonist of the GLP-1, GIP and glucagon receptors, licensed outside Greater China to Kailera Therapeutics.
What it's used for
An experimental weekly shot for weight loss and fatty liver that works three gut-hormone receptors at once. The only human data so far come from a 102-person phase 1.
How does KAI-4729 work?
What it does in the body, and where.KAI-4729 activates three receptors at once, adding glucagon to the GLP-1 and GIP pair that tirzepatide works.
- 01GLP-1 and GIP receptorsAppetite, stomach emptying and the insulin response after meals. Kailera reports 1.6 times retatrutide's GLP-1 receptor affinity in cell assays, with similar GIP affinity.
- 02Glucagon receptorPushes the liver to burn fat and raises energy expenditure. In the phase 1 this showed up as a large fall in liver fat and in triglycerides.
- 03Weekly, but shorter than its stablemateHalf-life of 4 to 5 days supports weekly dosing with little build-up. Ribupatide, the dual agonist from the same developer, lasts 7 to 8 days.
Hits 3 receptors at once.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Weight loss
Early research- Human trialPhase 1, 12 weeks, 10 people per arm: weight fell 8.7% at 1 mg, 12.8% at 4 mg, 12.5% at 8 mg and 16.0% at 12 mg weekly, against 4.9% on placebo. Between 70% and 91% of treated people lost at least 5%.
- Human trialRibupatide 4 mg, the active control in the same study, produced 16.7% in its ten people, so the triple agonist did not outperform its dual-agonist stablemate at these doses and this duration.
- No dataThis is a phase 1 secondary endpoint in ten people per arm. The press releases give the placebo figure as 5.4%; the poster gives 4.9%. The discrepancy is unexplained.
Liver fat and lipids
Early research- Human trialLiver fat fell 67% at 4 and 8 mg over 12 weeks, against 17% on placebo. The 12 mg arm showed 39%, so the effect was not dose-ordered in the whole group; Hengrui's dose-dependence claim is for people who started with at least 8% liver fat.
- Human trialTriglycerides fell 1.41 mmol/L and total cholesterol 1.05 mmol/L at 12 mg, larger falls than on ribupatide.
KAI-4729 is not retatrutide. Both hit the same three receptors and both were tested on a 1, 4, 8 and 12 mg weekly ladder, but they are different peptides from different companies; Kailera's filing names retatrutide as the reference drug it was designed to improve on. It is not ribupatide either, although ribupatide was the active control in its phase 1. The 16% figure is a phase 1 result in ten people at 12 weeks. The 67% liver-fat figure belongs to the 4 and 8 mg arms, not the 12 mg arm. Press releases say placebo lost 5.4%; the poster says 4.9%. The roughly seven-day half-life in Kailera's filing is ribupatide's; this compound's is 4 to 5 days.
The published record
Papers and trials about KAI-4729
5 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
5 registered trials · none with posted results
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about KAI-4729
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
About 4 to 5 days
How much, and do you cycle it?
The range, and whether you take breaks.1 up to 12 mg per week (trial doses), weekly. Not cycled in the trial Trial dose
Given weekly for the whole 12-week study with the dose stepped up at the start. Nothing longer has been tested.
How long does it stay in the body?
The half-life, and where the figure comes from.About 4 to 5 daysTrial protocol
Shorter than ribupatide's 7 to 8 days and retatrutide's roughly 6 days. Accumulation ratio with weekly dosing was 1.7.
Source: Hengrui, EASD 2026 poster LBA 41 (geometric mean 4.1 to 4.9 days across 0.2 to 9 mg single doses)
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized KAI-4729 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Any history of pancreatitis, gastric emptying problems or prior stomach surgery, excluded from its trials
- Diabetes, excluded from the phase 1 and the phase 2 in obesity
- Depression, suicidal thoughts or a prior attempt, excluded from the phase 2
- Pregnancy or breastfeeding
- Anyone who wants established safety data, because 12 weeks is the longest anyone has taken it
Stop and get help
- Severe stomach pain spreading to your back, a possible sign of pancreatitis
- Vomiting badly enough that you cannot keep fluids down
- A racing heartbeat, since glucagon-receptor drugs can raise heart rate and this one's heart-rate data are unpublished
- Spreading hives, swelling of the face or throat, or trouble breathing
Common effects
- Nausea in 37% and vomiting in 27% of people over 12 weeks of weekly dosing, against none on placebo
- Diarrhoea in 7%, abdominal bloating in 7%
- All events mild or moderate; no one stopped for a side effect in the phase 1
- Heart rate, liver enzymes and antibody results have not been reported
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is KAI-4729 approved?
And where the numbers on this page come from.No. KAI-4729 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked10 October 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesHengrui, EASD 2026 late-breaking poster LBA 41, phase 1 of HRS-4729ClinicalTrials.gov, HRS-4729-101 phase 1 (NCT06762600)ClinicalTrials.gov, HRS-4729-202 phase 2 in obesity (NCT07690826)Kailera Therapeutics, Q1 2026 results (26 May 2026)Kailera Therapeutics, Form S-1 (27 Mar 2026)Jiangsu Hengrui, SSE announcement 2024-153 (11 Dec 2024), via China Securities JournalFDA GSRS search, no record for HRS-4729 or KAI-4729
What has happened recently
Not approved anywhere. China's NMPA has approved clinical trials in obesity (December 2024), fatty liver disease (September 2025), type 2 diabetes (August 2026) and chronic kidney disease (September 2026). No US IND has been disclosed; Kailera plans its own phase 1 outside China by the end of 2026 with data in 2027.
You can compare this against the whole library, or read how to check a seller.
What else is like KAI-4729?
Others in GLP-1 agonists, side by side.If you're weighing KAI-4729, it's worth reading Lixisenatide (Adlyxin), MariTide (maridebart cafraglutide), and MBX 4291 in the same class.
An experimental weekly GLP-1/GIP/glucagon triple agonist, not to be confused with retatrutide.
- Dose
- 1 up to 12 mg per week (trial doses)
- How often
- Weekly
An approved GLP-1 that lost the race and left the US market.
- Dose
- Set by the label
- How often
- Once daily
An experimental once-a-month obesity shot.
- Dose
- 140 up to 420 mg per month (trial doses)
- How often
- Monthly
An experimental once-monthly GLP-1/GIP prodrug in its first human trial.
- Dose
- 30 mg weekly for 4 weeks, then 120 to 180 mg monthly (trial regimens)
- How often
- Weekly, then monthly (trial regimens)
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Hengrui, EASD 2026 late-breaking poster LBA 41, phase 1 of HRS-4729(2026)102 adults. Multiple-dose part, 60 people, 12 weeks: weight change 8.7%, 12.8%, 12.5% and 16.0% at 1, 4, 8 and 12 mg weekly against 4.9% on placebo (n=9) and 16.7% on ribupatide 4 mg (n=10). Half-life 4.1 to 4.9 days. Nausea 37%, vomiting 27%; no serious events or discontinuations.
- ClinicalTrials.gov, HRS-4729-101 phase 1 (NCT06762600)(2026)Randomised, double-blind, placebo-controlled single- and multiple-dose study in 102 adults at Jinan Central Hospital, completed 12 March 2026. Ribupatide (HRS9531) was the active control.
- ClinicalTrials.gov, HRS-4729-202 phase 2 in obesity (NCT07690826)(2026)252 adults with BMI 28 to 40 and no diabetes, six weekly dose levels against placebo, primary endpoint weight at 32 weeks. Not yet recruiting as of July 2026; estimated completion July 2027.
- Kailera Therapeutics, Q1 2026 results (26 May 2026)(2026)Phase 1 topline: linear pharmacokinetics, half-life about 4 to 5 days, weight loss up to 16.0% at 12 weeks on 12 mg against 5.4% on placebo, dose-dependent liver fat reduction. Hengrui to run phase 2 in China; Kailera to start a global phase 1 in 2026.
- Kailera Therapeutics, Form S-1 (27 Mar 2026)(2026)Based on a different peptide from ribupatide. Designed against retatrutide as the reference drug: 1.6x GLP-1 receptor binding affinity and similar GIP and glucagon receptor potency in a cell-based assay. No head-to-head trials have been run.
- Jiangsu Hengrui, SSE announcement 2024-153 (11 Dec 2024), via China Securities Journal(2024)NMPA approval to begin clinical trials of HRS-4729 in overweight and obesity; described as a GLP-1R/GIPR/GCGR triple agonist peptide; no similar product approved anywhere.
- FDA GSRS search, no record for HRS-4729 or KAI-4729(2026)No substance record, INN or published sequence exists. Retatrutide, by contrast, has UNII NOP2Y096GV and a published 39-residue sequence.
Beyond these, 5 records are indexed. Browse the records